These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases. Yang L, Zhang H, Zhang X, Tang Y, Wu Z, Wang Y, Huang H, Fu X, Liu J, Hogendoorn PCW, Cheng H. Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868 [Abstract] [Full Text] [Related]
4. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A. J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802 [Abstract] [Full Text] [Related]
5. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R, Nakashima Y, Oda Y. Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742 [Abstract] [Full Text] [Related]
6. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Yamamoto H, Ishihara S, Toda Y, Oda Y. Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824 [Abstract] [Full Text] [Related]
7. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Lüke J, von Baer A, Schreiber J, Lübbehüsen C, Breining T, Mellert K, Marienfeld R, Schultheiss M, Möller P, Barth TFE. Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081 [Abstract] [Full Text] [Related]
8. Current concepts in the treatment of giant cell tumour of bone. van der Heijden L, Dijkstra S, van de Sande M, Gelderblom H. Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321 [Abstract] [Full Text] [Related]
9. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS. Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281 [Abstract] [Full Text] [Related]
14. Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone. Wągrodzki M, Tysarowski A, Seliga K, Wojnowska A, Stepaniuk M, Castañeda Wysocka P, Makuła D, Pieńkowski A, Szostakowski B, Zub R, Rutkowski P. Int J Mol Sci; 2022 Jan 16; 23(2):. PubMed ID: 35055156 [Abstract] [Full Text] [Related]
15. Updated concepts in treatment of giant cell tumor of bone. van der Heijden L, Lipplaa A, van Langevelde K, Bovée JVMG, van de Sande MAJ, Gelderblom H. Curr Opin Oncol; 2022 Jul 01; 34(4):371-378. PubMed ID: 35837707 [Abstract] [Full Text] [Related]
16. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone. Ud Din N, Umer M, Park YK. Int J Surg Pathol; 2020 Dec 01; 28(8):859-867. PubMed ID: 32429739 [Abstract] [Full Text] [Related]
20. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors. Gong L, Bui MM, Zhang W, Sun X, Zhang M, Yi D. Histol Histopathol; 2021 Jan 01; 36(1):61-68. PubMed ID: 33021329 [Abstract] [Full Text] [Related] Page: [Next] [New Search]